Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis

0 Followers

Immuno-Biological Laboratories Co., Ltd.

(TSE/TYO:4570)

Select Model

Rating:70Outperform

Price Target:JPY 1,024.00▲(11.67% Upside)

Action:reiterated

Date:09/08/26

Score is primarily supported by a strong financial turnaround (high margins, improved ROE, low leverage, and positive free cash flow in the latest year). Technicals add moderate support with price above shorter-term moving averages and positive MACD, though being below the 200-day average limits the technical score. Valuation is the main drag due to a relatively high P/E and a low dividend yield.

Positive Factors

Strong Profitability RecoveryThe latest annual period shows a broad earnings recovery, with high gross and operating margins indicating attractive economics in the company’s research-reagent business. If sustained, this profitability can fund product development, support resilience through demand variation, and strengthen internal cash generation.

Negative Factors

Profitability VolatilityThe recent turnaround has not yet established a long record of dependable profitability. Losses as recently as 2023 indicate that earnings power may be sensitive to business conditions or execution, making the durability of current margins and returns an important medium-term risk.

Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 8.54B
Dividend Yield: 0.65%
Average Volume (3M): 128.03K
Price to Earnings (P/E): 22.8
Beta (1Y): 1.02
Revenue Growth: 7.10%
EPS Growth: 17.17%
Country: Japan
Employees: 54
Sector: General
Sector Strength: 55
Industry: Biotechnology

Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model

Company Description

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quanti...

Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview

Summary

Strong turnaround with robust latest-year profitability and improving revenue (2026 revenue +~5.6%, gross margin ~69.7%, operating margin ~28.0%, net margin ~32.7%). Balance sheet is conservative with low leverage (debt-to-equity ~0.10) and improved ROE (~17.8%). Main risk is durability given large losses and uneven cash-flow history in 2021–2025 despite strong 2026 FCF (~¥268M).

Income Statement

78Positive

Balance Sheet

86Very Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	1.08B	1.00B	969.53M	816.70M	794.62M	647.58M
Gross Profit	777.51M	700.28M	628.34M	517.29M	526.71M	376.70M
EBITDA	368.36M	299.82M	226.55M	128.11M	-279.54M	-127.50M
Net Income	368.32M	329.01M	249.05M	186.69M	-289.73M	-258.77M
Balance Sheet
Total Assets	2.23B	2.16B	1.85B	1.62B	1.43B	1.71B
Cash, Cash Equivalents and Short-Term Investments	907.94M	989.47M	825.73M	734.14M	614.16M	508.35M
Total Debt	171.81M	177.09M	204.23M	235.98M	234.99M	234.00M
Total Liabilities	338.30M	311.75M	332.03M	354.25M	355.72M	336.99M
Stockholders Equity	1.89B	1.84B	1.51B	1.27B	1.08B	1.37B
Cash Flow
Free Cash Flow	0	267.68M	123.83M	115.11M	26.46M	-93.20M
Operating Cash Flow	0	301.09M	183.50M	133.78M	26.46M	-93.20M
Investing Cash Flow	0	-116.46M	-53.66M	-24.50M	30.04M	-155.63M
Financing Cash Flow	0	-27.14M	-31.75M	991.00K	991.00K	144.00M

Immuno-Biological Laboratories Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative

Last Price917.00

Price Trends

50DMA1075.14Negative

100DMA1032.58Negative

200DMA1209.44Negative

Market Momentum

MACD-39.29Positive

RSI35.12Neutral

STOCH31.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 917.00 is below the 20-day moving average (MA) of 995.65, below the 50-day MA of 1075.14, and below the 200-day MA of 1209.44, indicating a bearish trend. The MACD of -39.29 indicates Positive momentum. The RSI at 35.12 is Neutral, neither overbought nor oversold. The STOCH value of 31.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.

Immuno-Biological Laboratories Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JP:4570 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4570	70Outperform	JPY 8.67B	22.84	―	0.65%	7.10%	17.17%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
JP:4978	45Neutral	JPY 11.65B	-25.06	―	―	-8.23%	-48.10%
JP:7774	42Neutral	JPY 26.88B	-73.78	―	―	17.05%	10.47%
JP:7776	39Underperform	JPY 6.70B	-5.83	―	―	-56.16%	3.12%
JP:4599	38Underperform	JPY 7.46B	-3.94	―	―	―	4.85%

* General Sector Average

Performance Comparison

JP:4570 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4570	Immuno-Biological Laboratories Co., Ltd.	917.00	69.63	8.22%
JP:4599	StemRIM Inc.	117.00	-161.00	-57.91%
JP:4978	ReproCELL Inc.	109.00	-48.00	-30.57%
JP:7774	Japan Tissue Engineering Co., Ltd.	653.00	175.00	36.61%
JP:7776	CellSeed Inc.	169.00	-232.00	-57.86%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 08, 2026

Immuno-Biological Laboratories Co., Ltd. AI Stock Analysis